NASDAQ:NITE - Nightstar Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.14 -0.86 (-5.38 %) (As of 11/20/2018 04:00 PM ET)Previous Close$16.00Today's Range$14.7650 - $15.8452-Week Range$9.59 - $29.55Volume228,521 shsAverage Volume86,732 shsMarket Capitalization$422.90 millionP/E Ratio-9.29Dividend YieldN/ABeta3.51 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom. Receive NITE News and Ratings via Email Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NITE Previous Symbol CUSIPN/A Webwww.nightstartx.com Phone646-522-8445 Debt Debt-to-Equity RatioN/A Current Ratio7.68 Quick Ratio9.95 Price-To-Earnings Trailing P/E Ratio-9.29 Forward P/E Ratio-10.30 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$4.48 per share Price / Book3.38 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees23 Outstanding Shares28,100,000Market Cap$422.90 million OptionableNot Optionable Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions What is Nightstar Therapeutics' stock symbol? Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE." How were Nightstar Therapeutics' earnings last quarter? Nightstar Therapeutics PLC (NASDAQ:NITE) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.13. View Nightstar Therapeutics' Earnings History. When is Nightstar Therapeutics' next earnings date? Nightstar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for Nightstar Therapeutics. What price target have analysts set for NITE? 8 brokerages have issued 1-year price objectives for Nightstar Therapeutics' shares. Their predictions range from $24.00 to $41.00. On average, they anticipate Nightstar Therapeutics' share price to reach $34.4286 in the next year. This suggests a possible upside of 127.4% from the stock's current price. View Analyst Price Targets for Nightstar Therapeutics. What is the consensus analysts' recommendation for Nightstar Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nightstar Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nightstar Therapeutics. What are Wall Street analysts saying about Nightstar Therapeutics stock? Here are some recent quotes from research analysts about Nightstar Therapeutics stock: 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (11/15/2018) 2. Mizuho analysts commented, "We attended Nightstar’s R&D Day yesterday where management presented preliminary data from the dose escalation study of NSR-RPGR for the treatment of X-Linked Retinitis Pigmentosa. We were encouraged by early signals observed in all cohort 3 patients and 2/6 patients in cohorts 4 and 5. However, the therapeutic dose to be taken into the upcoming expansion study remains to be determined as higher dose responders required a second course of steroids to control mild sub-retinal inflammation. The next important catalyst for the shares will be 2Q19 with six-months follow-up data from the dose escalation study. We maintain our Buy rating on the stock." (9/25/2018) Has Nightstar Therapeutics been receiving favorable news coverage? News headlines about NITE stock have been trending positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nightstar Therapeutics earned a news impact score of 2.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. Are investors shorting Nightstar Therapeutics? Nightstar Therapeutics saw a drop in short interest during the month of October. As of October 15th, there was short interest totalling 357,715 shares, a drop of 39.9% from the September 28th total of 595,093 shares. Based on an average daily trading volume, of 151,258 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.3% of the company's stock are sold short. View Nightstar Therapeutics' Current Options Chain. Who are some of Nightstar Therapeutics' key competitors? Some companies that are related to Nightstar Therapeutics include Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Spark Therapeutics (ONCE), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Solid Biosciences (SLDB), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), DBV TECHNOLOGIE/S (DBVT), Acorda Therapeutics (ACOR), Cellectis (CLLS), BioCryst Pharmaceuticals (BCRX) and Coherus Biosciences (CHRS). Who are Nightstar Therapeutics' key executives? Nightstar Therapeutics' management team includes the folowing people: Mr. David Fellows, CEO & Director (Age 61)Mr. Senthil Sundaram, Chief Financial Officer (Age 40)Dr. Gregory Robinson, Chief Scientific Officer (Age 59)Brian Luque, Sr. Mang. of Investor RelationsMr. Bryan Yoon, Gen. Counsel & Sec. (Age 40) When did Nightstar Therapeutics IPO? (NITE) raised $76 million in an IPO on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers. Who are Nightstar Therapeutics' major shareholders? Nightstar Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (7.41%), Point72 Asset Management L.P. (5.43%), Tekla Capital Management LLC (0.53%), Renaissance Technologies LLC (0.29%), Monashee Investment Management LLC (0.25%) and Citadel Advisors LLC (0.24%). Which major investors are selling Nightstar Therapeutics stock? NITE stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. Which major investors are buying Nightstar Therapeutics stock? NITE stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Redmile Group LLC, Tekla Capital Management LLC, Renaissance Technologies LLC, Monashee Investment Management LLC, Citadel Advisors LLC, JPMorgan Chase & Co. and JPMorgan Chase & Co.. How do I buy shares of Nightstar Therapeutics? Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nightstar Therapeutics' stock price today? One share of NITE stock can currently be purchased for approximately $15.14. How big of a company is Nightstar Therapeutics? Nightstar Therapeutics has a market capitalization of $422.90 million. The company earns $-29,680,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Nightstar Therapeutics employs 23 workers across the globe. What is Nightstar Therapeutics' official website? The official website for Nightstar Therapeutics is http://www.nightstartx.com. How can I contact Nightstar Therapeutics? Nightstar Therapeutics' mailing address is 81 HARTWELL AVE. SUITE 100, LEXINGTON MA, 02421. The company can be reached via phone at 646-522-8445 or via email at [email protected] MarketBeat Community Rating for Nightstar Therapeutics (NASDAQ NITE)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 140 (Vote Outperform)Underperform Votes: 116 (Vote Underperform)Total Votes: 256MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: How can you know how many shares are floating?